Page 476 - 16Neonatal Jaundice_compressed

Appendix H: Evidence tables

Bibliographic Study Type & Number of Intervention & Comparison Dichotomous outcomes Continuous Outcomes Comments
Information Evidence Level Patients/Characteristics (E:C) (Mean:SD: N)

Author: Methodology: N: Group 1: Mortality: Mean duration of treatment:
Miqdad A RCT 112 Phototherapy Group 1: 4/56 Group 1: 106 ± 29 hours
Group 2: 16/56
Year: Blinding: Inclusion: Group 2: Group 2: 92 ± 29 hours
2004 Not reported Hyperbilirubinaemia due to Phototherapy + IVIG 500 mg/kg body
ABO incompatibility weight over 4 hours
Country: Randomisation:
Saudi Arabia Not reported Exclusion:
Low birthweight,
206
ID: Evidence level: Rh haemolytic disease,,
1 - Perinatal asphyxia, severe
congenital malformations

Demographics:
Gender (M/F): 70/42
Mean GA: 38 weeks
Mean BW: Not reported
Age at entry to study:
Not reported
Mean TSB: Not reported
Author: Methodology: N: Group 1: Exchange transfusion:
Voto L RCT 40 Phototherapy Group 1: 8/19
Group 2: 12/18
Year: Blinding: Inclusion: Group 2:
1997 Not reported Rh positive blood type and Phototherapy + IVIG 800 mg/kg body No adverse effects were
Positive Coombs’ test weight per day for 3 days noted
Country: Randomisation:
Argentina Not reported Exclusion:
Rh positive blood and
205
ID: Evidence level: negative Coombs’ test,
1 - Histroy of prenatal therapy
(Imaternal IVIG/IUT)
ABO incompatibility,
Other causes of haemolyisis

Demographics:
Gender (M/F): Not reported
Mean GA: 37.2 ± 2.7
Mean BW: 2834 ± 569 g
Age at entry to study: Not
reported
Mean TSB: Not reported
Author: Methodology: N: Group 1: Exchange transfusion: Max TsB: Prevention study
Rubo J RCT 32 Phototherapy Group 1: 11/16 Group 1: 240 ± 78 micromol/litre
Group 2: 2/16 One baby in each
Year: Blinding: Inclusion: Group 2: Group 2: 254 ± 86 micromol/litre: group excluded for

311